Ironwood Pharma Discloses Exit Costs & Officer Changes

TL;DR

Ironwood Pharma's 8-K: Exit costs, exec departures, new hires. Big changes brewing.

AI Summary

Ironwood Pharmaceuticals, Inc. reported on January 17, 2025, regarding costs associated with exit or disposal activities, and also disclosed the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. The company is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing indicates potential restructuring or strategic shifts within Ironwood Pharmaceuticals, which could impact its operational focus and financial performance.

Risk Assessment

Risk Level: medium — The filing details changes in leadership and potential exit costs, which can signal uncertainty or significant strategic shifts for the company.

Key Players & Entities

• IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Boston, Massachusetts (location) — Principal executive offices
• 001-34620 (company_id) — Commission File Number
• 04-3404176 (company_id) — I.R.S. Employer Identification Number

FAQ

Key Financial Figures

• $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
• $20.0 million — ncur aggregate charges of approximately $20.0 million to approximately $25.0 million, primari
• $25.0 m — ximately $20.0 million to approximately $25.0 million, primarily comprised of one-time
• $485,000 — . Martini will receive a base salary of $485,000 a year and will have an individual bonu

Filing Documents

• tm254830d1_8k.htm (8-K) — 33KB
• 0001104659-25-007212.txt ( ) — 204KB
• irwd-20250117.xsd (EX-101.SCH) — 3KB
• irwd-20250117_lab.xml (EX-101.LAB) — 33KB
• irwd-20250117_pre.xml (EX-101.PRE) — 22KB
• tm254830d1_8k_htm.xml (XML) — 4KB

05 Costs Associated

Item 2.05 Costs Associated with Exit or Disposal Activities. Following an analysis of Ironwood Pharmaceuticals, Inc.'s (the "Company") strategy and core business needs, and in an effort to streamline focus and support the continued development of the Company's pipeline, on January 17, 2025, the Board of Directors of the Company approved a reduction in the Company's workforce of approximately 50%, primarily consisting of field-based sales employees. Affected employees were notified on January 29, 2025. This reduction in workforce is expected to be substantially completed by the end of the first half of 2025, following which the Company expects to have approximately 120 full-time employees. The Company estimates that, in connection with this reduction in its workforce, it will incur aggregate charges of approximately $20.0 million to approximately $25.0 million, primarily comprised of one-time employee severance and benefit costs. The charges related to the reduction in workforce are expected to be substantially incurred in the first half of 2025. Of these charges, substantially all are expected to result in cash expenditures. The Company may incur additional costs not currently contemplated due to events associated with or resulting from the workforce reduction. The estimated charges that the Company expects to incur are subject to a number of assumptions, and actual results may differ materially from these estimates.

02 Departure of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Also on January 29, 2025, the Company announced the promotion of Gregory Martini, 36, to Senior Vice President, Chief Financial Officer. Mr. Martini's promotion was effective as of January 27, 2025. Mr. Martini will assume the responsibilities of the Company's principal financial officer from Thomas McCourt, who will remain the Company's principal executive officer. Mr. Martini has been the Company's Vice President, Strategic Finance & Investor Relations since March 2022. Mr. Martini joined the Company in 2017 and previously served as Senior Director, Financial Planning & Analysis from 2020 to 2022 and as Director, Financial Planning & Analysis from 2019 to 2020. Prior thereto, he served in various financial planning & analysis roles of increasing responsibility enterprise-wide, supporting the commercial, research and development, and general and administrative functions. Before joining the Company, Mr. Martini served in various financial and corporate development roles at Thermo Fisher Scientific, Ernst & Young and Raytheon. Mr. Martini holds a B.S. in finance from Bentley University. As the Company's Senior Vice President, Chief Financial Officer, Mr. Martini will receive a base salary of $485,000 a year and will have an individual bonus target of 45% of his base salary, subject to achievement of individual and corporate goals. In addition, on January 27, 2025, Mr. Martini received a grant of 111,111 restricted stock units ("RSUs") representing the right to receive shares of the Company's Class A common stock upon vesting of such awards granted under the Company's 2019 Amended and Restated Equity Incentive Plan. The RSUs will vest over four years as to 25% of the RSUs on each approximate anniversary of the date of grant. In addition, the Company will enter into an indemnification agreement and an execut

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: January 29, 2025 By: /s/ Thomas McCourt Name: Thomas McCourt Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR